Rosamond Deegan (OMass)
University of Oxford spinoff nets a nine-figure Series B, but it won't beeline toward the clinic
Four years after completing a Series A, an Oxford spinout has returned to the venture well and garnered interest for how its technology is being applied to drug discovery.
OMass Therapeutics has raised $100 million in a Series B round with participants that include GV, Northpond Ventures and Sanofi Ventures. Syncona, Oxford Science Enterprises and the University of Oxford, who were a part of the Series A round, also participated this time around.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
